Covid-19 transmission, outcome and associated risk factors in cancer patients at the first month of the pandemic in a Spanish hospital in Madrid
BACKGROUND: There are no large reported series determining the Covid-19 cancer patient's characteristics. We determine whether differences exist in cumulative incidence and mortality of Covid-19 infection between cancer patients and general population in Madrid.
MATERIAL AND METHODS: We reviewed 1069 medical records of all cancer patients admitted at Oncology department between Feb 1 and April 7, 2020. We described Covid-19 cumulative incidence, treatment outcome, mortality, and associated risk factors.
RESULTS: We detected 45/1069 Covid-19 diagnoses in cancer patients vs 42,450/6,662,000 in total population (p < 0.00001). Mortality rate: 19/45 cancer patients vs 5586/42,450 (p = 0.0001). Mortality was associated with older median age, adjusted by staging and histology (74 vs 63.5 years old, OR 1.06, p = 0.03). Patients who combined hydroxychloroquine and azithromycin presented 3/18 deaths, regardless of age, staging, histology, cancer treatment and comorbidities (OR 0.02, p = 0.03).
CONCLUSION: Cancer patients are vulnerable to Covid-19 with an increase in complications. Combined hydroxychloroquine and azithromycin is presented as a good treatment option.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 22(2020), 12 vom: 24. Dez., Seite 2364-2368 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rogado, J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4QWG6N8QKH |
|---|
| Anmerkungen: |
Date Completed 02.11.2020 Date Revised 10.01.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12094-020-02381-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310312965 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310312965 | ||
| 003 | DE-627 | ||
| 005 | 20231225135827.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12094-020-02381-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1034.xml |
| 035 | |a (DE-627)NLM310312965 | ||
| 035 | |a (NLM)32449128 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rogado, J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Covid-19 transmission, outcome and associated risk factors in cancer patients at the first month of the pandemic in a Spanish hospital in Madrid |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.11.2020 | ||
| 500 | |a Date Revised 10.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: There are no large reported series determining the Covid-19 cancer patient's characteristics. We determine whether differences exist in cumulative incidence and mortality of Covid-19 infection between cancer patients and general population in Madrid | ||
| 520 | |a MATERIAL AND METHODS: We reviewed 1069 medical records of all cancer patients admitted at Oncology department between Feb 1 and April 7, 2020. We described Covid-19 cumulative incidence, treatment outcome, mortality, and associated risk factors | ||
| 520 | |a RESULTS: We detected 45/1069 Covid-19 diagnoses in cancer patients vs 42,450/6,662,000 in total population (p < 0.00001). Mortality rate: 19/45 cancer patients vs 5586/42,450 (p = 0.0001). Mortality was associated with older median age, adjusted by staging and histology (74 vs 63.5 years old, OR 1.06, p = 0.03). Patients who combined hydroxychloroquine and azithromycin presented 3/18 deaths, regardless of age, staging, histology, cancer treatment and comorbidities (OR 0.02, p = 0.03) | ||
| 520 | |a CONCLUSION: Cancer patients are vulnerable to Covid-19 with an increase in complications. Combined hydroxychloroquine and azithromycin is presented as a good treatment option | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Covid-19 | |
| 650 | 4 | |a Cumulative incidence | |
| 650 | 4 | |a Metastatic | |
| 650 | 4 | |a Mortality | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 650 | 7 | |a Azithromycin |2 NLM | |
| 650 | 7 | |a 83905-01-5 |2 NLM | |
| 700 | 1 | |a Obispo, B |e verfasserin |4 aut | |
| 700 | 1 | |a Pangua, C |e verfasserin |4 aut | |
| 700 | 1 | |a Serrano-Montero, G |e verfasserin |4 aut | |
| 700 | 1 | |a Martín Marino, A |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Pérez, M |e verfasserin |4 aut | |
| 700 | 1 | |a López-Alfonso, A |e verfasserin |4 aut | |
| 700 | 1 | |a Gullón, P |e verfasserin |4 aut | |
| 700 | 1 | |a Lara, M Á |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico |d 2005 |g 22(2020), 12 vom: 24. Dez., Seite 2364-2368 |w (DE-627)NLM155341065 |x 1699-3055 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2020 |g number:12 |g day:24 |g month:12 |g pages:2364-2368 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12094-020-02381-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2020 |e 12 |b 24 |c 12 |h 2364-2368 | ||